Registry following adults with multiple sclerosis and their treatments over time
Observes how approved multiple sclerosis treatments work and their safety in adults.
Plain-language title generated from the registry record
Registry title: CorEvitas Multiple Sclerosis (MS) Registry
Key facts
- Where
- Waltham, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis (MS) who are starting a listed MS medicine at enrollment. It only follows their care and does not assign treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of multiple sclerosis at enrollment. No specific stage or severity is stated.
- Earlier treatment
- Must be starting (prescribed or beginning) a listed MS medicine at the enrollment visit.
Main reasons for not taking part
- Taking part, or planning to take part, in a double-blind randomized trial for an MS drug
- Not willing to provide personal information
Read by machine on 12 November 2026.
Where in United States
- CorEvitas, LLCWaltham, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CorEvitas
- Trial code
- NCT03291756
- Record updated
- 9 February 2026
- Original description
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.Read full original descriptionShow less
CorEvitas Multiple Sclerosis (MS) Registry
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Inclusion: Has a diagnosis of MS at the time of enrollment; Age 18 years or older at the time of enrollment; Willing to provide Personal Information; Initiating (prescribed or starting) an Eligible Medication for the treatment of MS at the enrollment visit.
Exclusion: Is participating or planning to participate in a double-blind randomized trial for an MS drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.